LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Aandelen Lijst・Roivant Sciences Ltd

Roivant Sciences Ltd

Gesloten

SectorGezondheidszorg

30.84 -4.81

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.74

Max

32.68

Belangrijke statistieken
By Trading Economics
Inkomsten	-200M -314M
Verkoop	428K 2M
Winstmarge	-15,692.896
Werknemers	750
EBITDA	-132M -290M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+26.52% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4.9B 20B
Vorige openingsprijs	35.65
Vorige sluitingsprijs	30.84

Nieuwssentiment

By Acuity

11%

89%

13 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

11 / 11.18 Steun & Weerstand

Roivant Sciences Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mei 2026, 22:52 UTC

Belangrijke Marktbewegers

Osisko Shares Fall on Planned Convertible Notes Offering

20 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mei 2026, 23:44 UTC

Winsten

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mei 2026, 23:35 UTC

Marktinformatie

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mei 2026, 23:30 UTC

Marktinformatie

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mei 2026, 23:15 UTC

Marktinformatie

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mei 2026, 23:14 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mei 2026, 23:02 UTC

Marktinformatie

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 22:27 UTC

Marktinformatie

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mei 2026, 22:14 UTC

Marktinformatie

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mei 2026, 22:10 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mei 2026, 22:00 UTC

Winsten

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mei 2026, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mei 2026, 21:27 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mei 2026, 21:20 UTC

Winsten

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mei 2026, 21:19 UTC

Winsten

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mei 2026, 21:18 UTC

Winsten

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mei 2026, 21:17 UTC

Winsten

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mei 2026, 21:16 UTC

Winsten

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Vergelijking

Prijswijziging

Roivant Sciences Ltd Prognose

Koersdoel

By TipRanks

26.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.69 USD 26.52%

Hoogste 41 USD

Laagste 29.5 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Roivant Sciences Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Roivant Sciences Ltd - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11 / 11.18Steun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

13 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.